Navigation Links
Oncolytics Biotech(R) Inc. Announces Unit Offering
Date:11/17/2009

ks and uncertainties include, among others, the pricing and completion of the contemplated offering, availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
3. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
8. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
9. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
10. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
11. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... METTLER TOLEDO’s newly improved XS balance line includes ... as a dual range microbalance . As a ... pan delivers results up to twice as fast, even ... details mean users no longer need to suffer the ... front of the balance. Barbara Bienlein, medical specialist and ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Weighing ... quality of the final product. However, while the ... regulatory frameworks such as Good Manufacturing Practices (GMP) ... responsibility of the manufacturer to interpret these guidelines ... weighing performance quality. METTLER TOLEDO experts have created ...
(Date:10/1/2014)... As the world takes its first steps into ... this century would mark the beginning of a new era ... The fact that the world is experiencing a rapid rise ... community. Almost half of these chronic conditions are due to ... medical care and intervention. While the world is experiencing a ...
(Date:10/1/2014)... In response to its clients’ evolving ... training and consumer engagement challenges, digital agency ... to turn their clients’ visions into reality. New ... app creations, are now featured on its website ... Toyota, StudioPMG created a robust cross-platform mobile application ...
Breaking Biology Technology:METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3Comply with Weighing-Related Regulations in Pharma Manufacturing 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3Digital Agency Studio PMG Launches New Case Studies on Website 2
... from North Carolina State University shows that size plays ... hollow nanoparticles. The researchers focused on nickel nanoparticles, which ... applications in fields as diverse as energy production and ... potential for nanofabrication the creation of materials that ...
... push the boundaries of nanoscience, the Kavli Institute at Cornell ... new ideas, but a proving ground to aggressively push the ... named Paul McEuen, the Goldwin Smith Professor of Physics, as ... engineering physics, will serve as co-director. The institute ...
... Choi of the Department of Mechanical Engineering at Stevens ... the 2010 Young Investigator Program (YIP) award by the ... scientists and engineers who show exceptional promise for creative ... young outstanding scientists and engineers," said ONR,s Director of ...
Cached Biology Technology:Study shows that size affects structure of hollow nanoparticles 2Under new leadership, Kavli Institute at Cornell evolves from a think tank to a proving ground 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 3
(Date:9/30/2014)... England Journal of Medicine reports positive results of ... against the subset of lung cancer marked by rearrangement ... 50 patients with advanced non-small cell lung cancer testing ... 72 percent, with 3 complete responses and 33 partial ... for the disease to resume its growth after being ...
(Date:9/30/2014)... German . ... foods in the world. Because they grow underground, people use ... smell of truffles is not only of interest to gourmets. ... of the Goethe University Frankfurt have discovered that the smell ... are trapped inside truffle fruiting bodies. , White truffles from ...
(Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... in German . , Jena/Leipzig. For ... extended cultivation of energy crops. Scientists have now developed ... comparing the effectiveness of strategies for the reduction of ... leads to problems to biological diversity in agrarian regions. ...
... 2012  The Intellectual Property & Science division of ... information for businesses and professionals, today announced the ... the life sciences market, a new initiative aimed ... information through application-specific solutions developed with third-party partners. ...
... With more than 1.7 million people sustaining a traumatic ... to limit inflammation and subsequent damage is critical. Approximately ... leaving 85,000 with long-term disabilities and taking the lives ... live with disabilities caused by traumatic brain injuries, often ...
Cached Biology News:How the ecological risks of extended bioenergy production can be reduced 2How the ecological risks of extended bioenergy production can be reduced 3Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes 2Estrogen hormone reveals protective ability after traumatic brain injury 2
...
...
... Comments: Ab-1 stains tumor cells of embryonal ... type of germ cell tumors like seminoma. Glandular ... are positive. Luminal and endocrine cells of stomach ... breast are also positive. Epitope: Carbohydrate ...
TP-1 (NDOG1)...
Biology Products: